Sneha Sarkar: Comparative Safety and Effectiveness Profile of Direct Oral Anticoagulants in AF
Sneha Sarkar, PharmD Intern at ESIC – Employees’ State Insurance Corporation, shared a post on LinkedIn:
“Research Publication | Clinical Research and Evidence-Based Medicine
I am delighted to share our research article titled ‘Comparative Risk of Major Bleeding, Stroke, and Mortality Among Individual Direct Oral Anticoagulants: A Comparative-Effectiveness Review’.
This review explores the comparative safety and effectiveness of four Direct Oral Anticoagulants (DOACs) – Apixaban, Rivaroxaban, Dabigatran, and Edoxaban – in patients with Atrial Fibrillation (AF).
Key areas explored in this research:
- Comparative risk of major and clinically relevant bleeding.
- Stroke and systemic embolism outcomes.
- All-cause mortality associated with individual DOACs.
- Evidence synthesis from network meta-analyses and large observational cohort studies.
- Clinical implications for evidence-based anticoagulant selection.
Key learning: Although DOACs belong to the same therapeutic class, their comparative safety and effectiveness profiles may differ.
Understanding these differences is essential for informed clinical decision-making and individualized patient care.
Being part of this research journey has strengthened my interest in Clinical Research, Pharmacovigilance, Evidence-Based Medicine, and Clinical Data Interpretation.
Grateful for the opportunity to contribute to scientific research and expand my knowledge in the field of clinical pharmacy.”
Stay updated with Hemostasis Today.
-
Nov 7, 2026, 17:15Sophie Bots: In Situations Where RCTs and Observational Studies Do Not Align, Who Is ‘Right’?
-
Nov 7, 2026, 17:08Wolfgang Miesbach: Immune-Engineered AAV Capsids Displaying IL-10 Enhance Gene Therapy Safety and Efficacy
-
Nov 7, 2026, 17:03Nicole Dobkin: Survey Reveals Major Disconnect Between Access to Apheresis and Patient Utilization in Sickle Cell Care
-
Nov 7, 2026, 16:58Muhammad Essa: Comparing Indobufen and Aspirin in Acute Ischemic Stroke
-
Nov 7, 2026, 16:42Inderpaul Birdi: Warfarin or Newer Blood Thinners?
-
Nov 7, 2026, 16:31Arwa Z. Al-Riyami: EMR Transfusion Medicine Featured in October 2026 Issue of ISBT Transfusion Today
-
Nov 7, 2026, 16:31Rafael Gomes: Is Dual Antiplatelet Therapy Still Necessary After LAAO?
-
Nov 7, 2026, 16:15Mazyar Shadman: Novel BTK Inhibitors and DOACs A Multicenter Study of Bleeding Risk
-
Nov 7, 2026, 15:54Hassan Raza: Beyond the 100 Minus Age Rule in Bone Marrow Cellularity